131i Biokinetics and Cytogenetic Dose Estimates in Ablation Treatment of Thyroid Carcinoma

Nascimento, Ana Carolina; Lipsztein, J. L.; Corbo, Rossana; Rebelo, A M O

doi:10.1097/hp.0b013e3181c8f9ea

Cited by 16 publications

(10 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 29 30 ] have also shown that MN frequency, as a biomarker of cancer risk, might not be reliable if it was investigated in lymphocytes which were affected by intensive cells proliferation as well as an apoptosis processes. Other reports[ 31 32 33 ] confirmed a statistically significant increase of cytogenetic damage detected after therapy although authors stressed strong influence of time between exposure and biomarkers monitoring. Our report is in agreement with all above observations.…”

Section: Discussionmentioning

confidence: 94%

“…Nascimento et al . [ 31 ] evaluated the biokinetics of radioiodine in adult cancer patients from the 1 st hour following radioiodine administration until minimum detection limits were reached. Authors reported the exponential type of retention kinetics with two biological half-lives, 0.81 day from day 1 to day 6 after the I-131 intake, with increasing appearance later in urine, and after 2 weeks, the retention of iodine in the body followed an exponential decrease, with a half-life of about 15 days.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Retrospective Biological Dosimetry at Low and High Doses of Radiation and Radioiodine Impact on Individual Susceptibility to Ionizing Radiation

et al. 2017

View full text Add to dashboard Cite

Iodine-131 (I-131) is often used in thyroid diagnostics and therapy. External and internal exposure to radioiodine can lead to molecular and cellular damage in peripheral blood lymphocytes. The aim of this study was to explore the influence of low and high doses of I-131 on susceptibility to ionizing radiation. Study groups consisted of 30 individuals free of thyroid diseases, 41 patients exposed diagnostically to low doses of I-131, and 37 hyperthyroidism patients exposed therapeutically to high doses. The standardized DNA repair competence assay was used to test the efficacy of the fast DNA repair process in G0 cells. Cytogenetic preparations were made in fresh blood samples before and after challenging cells in vitro with X-ray dose. The frequency of sister chromatid exchanges (SCE) and percentage of cells with significantly elevated numbers of SCE were used as cytogenetic biomarkers associated to homologous recombination and compared to reported earlier cytogenetic biomarkers of cancer risk. Strong individual variation in the biomarkers is observed in all investigated groups before and after challenging. Nevertheless, the efficiency of post challenging fast repair is significantly high in the patients exposed to diagnostic I-131 doses than in unexposed control group and linked to decreased cytogenetic damage. However, 5 weeks after administration of therapeutic doses, significant increases of unrepaired post challenging DNA and cytogenetic damages were observed indicating a health risk. Results also suggest that the appearance of cancers in immediate families might influence DNA repair differently in patients exposed to low than to high doses.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Retrospective Biological Dosimetry at Low and High Doses of Radiation and Radioiodine Impact on Individual Susceptibility to Ionizing Radiation

et al. 2017

View full text Add to dashboard Cite

show abstract

“…analytical assessments listed in Table 3 were made based on the exponential decay of two compartments and defined as instant or slow decay terms for the numerical analysis [15][16][17][18]20]. The most intricate model of Guiu-Souto et al [19] included ten compartments and assigned two feedback paths (from body fluid to stomach and liver to body fluid), whereas others either had no assigned feedback path or defined only one feedback path.…”

Section: Plos Onementioning

confidence: 99%

Biokinetic model of radioiodine I-131 in nine thyroid cancer patients subjected to in-vivo gamma camera scanning: A simplified five-compartmental model

et al. 2020

View full text Add to dashboard Cite

A five-compartmental biokinetic model of I-131 radioiodine based on in-vivo gamma camera scanning results was developed and successfully applied to nine thyroid cancer patients who were administered 1,110 MBq I-131 in capsules for the residual thyroid gland ablation. The I-131 solution activity among internal organs was analyzed via the revised biokinetic model of iodine recommended by the ICRP-30 and-56 reports. Accordingly, a five-compartmental (stomach, body fluid, thyroid, whole body, and excretion) model was established to simulate the metabolic mechanism of I-131 in thyroid cancer patients, whereas the respective four simultaneous differential equations were solved via a self-developed program run in MATLAB. This made it possible to provide a close correlation between MATLAB simulation results and empirical data. The latter data were collected through in-vivo gamma camera scans of nine patients obtained after 1, 4, 24, 48, 72, and 168 hours after radioactive I-131 administration. The average biological half-life values for the stomach, body fluid, thyroid, and whole body of thyroid cancer patients under study were 0.54±0.32, 12.6±1.8, 42.8±5.1, and 12.6±1.8 h, respectively. The corresponding branching ratios I 12 , I 23 , I 25 , I 34 , I 42 , and I 45 as denoted in the biokinetic model of iodine were 1.0, 0.21±0.14, 0.79±0.14, 1.0, 0.1, and 0.9, respectively. The average values of the AT dimensionless index used to verify the agreement between empirical and numerical simulation results were 0.056±0.017, 0.017±0.014, 0.044±0.023, and 0.045±0.009 for the stomach, thyroid, body fluid + whole body, and total, respectively. The results obtained were considered quite instrumental in the elucidation of metabolic mechanisms in the human body, particularly in thyroid cancer patients.

show abstract

“…131 I therapy has been used for the ablation of well-differentiated thyroid carcinoma for more than six decades (21). This therapy is a rapid, stress-free, highly effective and simple for cats, dogs and people with hyperthyroidism (14,25).…”

Section: Introductionmentioning

confidence: 99%

Radioprotective effect of montelukast sodium against hepatic radioiodine (131I) toxicity: A histopathological investigation in the rat model

Atilgan¹,

Yumuşak²,

Sadic³

et al. 2015

Ankara Üniversitesi Veteriner Fakültesi Dergisi

View full text Add to dashboard Cite

Summary: Radioactive iodine (131 I) is a known radionuclide which is used both for diagnostic and therapeutic purposes in the treatment of hyperthyroidism and thyroid cancer. Montelukast sodium (Cysteinyl leukotriene receptor-1 antagonist) is also a wellknown antioxidant drug. This study aimed to evaluate the histopathological changes in rat livers at the third month following 131 I treatment and the radioprotective effect of Montelukast sodium (ML) against 131 I-related liver damage. Thirty female Wistar Albino rats were randomly divided into three groups as control group (n=10), untreated rats; second (RAI) group (n=10), oral radioiodine (111 MBq) administrated rats, and third (ML) group (n=10), oral radioiodine and ML administrated rats. In the third group, ML administration was started 3 days before and ended 10 days after RAI administration. In the third month of radioiodine (RAI) administration, the animals were decapitated and the livers were removed for histopathological examination. The histopathologic data were evaluated comparatively by using Mann Whitney U and Fisher's Exact Tests Differences were determined in all the parameters in terms of intensity between the control and 131 I groups, which showed the harmful effects of 131 I. In the comparison of the 131 I and ML groups, hyperemia was determined respectively 80% to 40%, the presence of inflammatory cells 70% to 60% and capsule thickening 70% to 40%. Montelukast sodium was observed to have a protective effect especially on hyperemia and capsule thickening. According to the study results, radioactive iodine ( 131 I) treatment seems to cause morphological damage to the rat liver, and Montelukast sodium effectively protects the liver against damage.Key words: Iodine-131, histopathology, liver, montelukast sodium, rat. Karaciğerde radyoiodin ( 131 İ) toksisitesine karşı montelukast sodyumun radyoprotektif etkisi: Rat modelinde histopatolojik incelemelerÖzet: Radyoaktif iyot ( 131 I) hipertiroidizm ve tiroid kanserlerinin tanı ve tedavisi amacıyla kullanılan bir radyonükliddir. Montelukast sodyum (Cysteinyl leukotriene receptor-1 inhibitörü) ise antioksidan olarak bilinen bir ilaçtır. Bu çalışma ile rat karaciğerinde radyoiodinden (RAI) kaynaklanan radyasyon hasarına karşı Montelukast sodyumun (ML) radyoprotektif etkisinin histopatolojik olarak değerlendirilmesi amaçlandı. Çalışmada 30 adet dişi Wistar Albino rat kullanıldı ve bunlar rastgele üç gruba ayrıldı; birinci grubu hiçbir işleme tabi tutulmayan kontrol grubu (n=10), ikinci (RAI) grubu, (n=10), oral olarak RAI (111 MBq) uygulanan ratlar, üçüncü (ML) grubunu ise (n=10) oral olarak RAI ve ML uygulanan grup oluşturdu. Üçüncü çalışma grubunda ML uygulaması RAI uygulamasından 3 gün önce başlatıldı ve 10 gün sonra bitirildi. Üçüncü ay sonunda nekropsileri yapılan ratların karaciğer doku örnekleri rutin doku takibine alınarak histopatolojik olarak incelendi. Radyoiodin ve ML grubunda tüm histopatolojik bulgular Mann Whitney U testi ve Fisher'in ekzak test ile karşılaştırılarak değerlendirildi. Bütün ...

show abstract

131i Biokinetics and Cytogenetic Dose Estimates in Ablation Treatment of Thyroid Carcinoma

Cited by 16 publications

References 12 publications

Retrospective Biological Dosimetry at Low and High Doses of Radiation and Radioiodine Impact on Individual Susceptibility to Ionizing Radiation

Retrospective Biological Dosimetry at Low and High Doses of Radiation and Radioiodine Impact on Individual Susceptibility to Ionizing Radiation

Biokinetic model of radioiodine I-131 in nine thyroid cancer patients subjected to in-vivo gamma camera scanning: A simplified five-compartmental model

Radioprotective effect of montelukast sodium against hepatic radioiodine (131I) toxicity: A histopathological investigation in the rat model

Contact Info

Product

Resources

About